Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients


The aim of the study is to evaluate the effect of Gelronate gel, NaHA based product (medical device for topical application) vs. Aloevera gel, in prevention or minimizing of radiation induced skin reaction in breast cancer patients

Full Title of Study: “Double Blind Study – Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: June 30, 2020

Detailed Description

Gelronate is gel composed of 1% high molecular weight pharmaceutical grade sodium hyaluronate and preservatives dissolved in pharmaceutical grade purified water. Gelronate supply in an airless pump bottle contain ~30 ml gel. In the study, 120 female patients planned to receive whole breast radiation (with or without lymphatic drainage) in the radiotherapy unit at Sheba Medical Center.

Patients will undergo CT simulation with 3D treatment planning (as routine done) and will receive 42.4 Gy in daily fraction of 2.65 Gy, five times per week to the whole breast according to the standard department protocol, with or without concomitant or subsequent lumpectomy cavity boost. Patients data including demographics, staging, systemic therapy, radiation details, other medications will be recorded the protocol's forms.

The gel will be applied as a thin lotion twice a day, immediately after radiotherapy treatment and once more in the evening/morning. The therapy will continue for 10 days following the end of radiation therapy.


  • Device: Gelronate
    • Gel for topical use
  • Other: Aloevera
    • Gel for topical use

Arms, Groups and Cohorts

  • Experimental: Gelronate
    • Tested new medical device
  • Active Comparator: Aloevera
    • Current product used by the medical center

Clinical Trial Outcome Measures

Primary Measures

  • Development and degree of any skin reaction
    • Time Frame: 4 weeks
    • Grading according to Radiation Toxicity Grading (RTOG) skin toxicity score. Full scale of RTOG is 0 (no change over baseline) to 4 (ulceration, hemorrhage, necrosis).
  • Development and degree of any skin reaction
    • Time Frame: 4 weeks
    • Assessment of skin reaction by scoring of weekly digital photographs
  • Development and degree of any skin reaction
    • Time Frame: 4 weeks
    • Patient comfort assessed by weekly administrated questionnaire. Scores are between 1 (nothing) to 4 (all over the breast)

Secondary Measures

  • Skin reaction requiring conventional topical therapy
    • Time Frame: 4 weeks
    • Skin reaction requiring conventional topical therapy (e.g. steroid cream etc.) as evaluated by clinical. judgment of radiotherapy nurse/radiation oncologist at OTV (on treatment view visit that will include RTOG (Radiation Toxicity Grading) scores (in the range 0 no change to 4 ulceration, hemorrhage, necrosis) and dermatology assessment according to the table in the protocol (general view range 1 (nothing) to 4 (continuous))

Participating in This Clinical Trial

Inclusion Criteria

  • Female patients aged at least 18 years with unilateral breast following lumpectomy +/ chemotherapy
  • Planned to receive 42.4 Gy whole breast irradiation +/- boost to tumor bed.
  • ECOG performance status 0-2.
  • Capable of giving written informed consent.
  • No co-morbidities known to affect radiotherapy reactions.
  • No co-existing acute or chronic skin disease.
  • No evidence of infection or inflammation of breast to be treated.
  • Not receiving chemotherapy during radiotherapy course. Biological therapy (e.g. Herceptin) or hormone therapy will be allowed during the study.

Exclusion Criteria

  • Chemotherapy within 4 weeks prior to planned start of radiation or chemotherapy planned during radiation.
  • Prior radiotherapy to the chest wall.
  • Collagen vascular disease.
  • Participation in other clinical study.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sheba Medical Center
  • Collaborator
    • Ferring Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ofer S Dubinsky, Ph.D., Study Director, Ferring Holding Ltd.

Citations Reporting on Results

Primavera G, Carrera M, Berardesca E, PinnarĂ³ P, Messina M, Arcangeli G. A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (XClair), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis. Cutan Ocul Toxicol. 2006;25(3):165-71.

Leonardi MC, Gariboldi S, Ivaldi GB, Ferrari A, Serafini F, Didier F, Mariani L, Castiglioni S, Orecchia R. A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis. Eur J Dermatol. 2008 May-Jun;18(3):317-21. doi: 10.1684/ejd.2008.0396. Epub 2008 May 13.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.